Literature DB >> 27506406

Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β.

Yixuan Zhai1, Jiwei Bai2, Shuai Wang1, Jiang Du3, Jichao Wang1, Chuzhong Li1, Songbai Gui2, Yazhuo Zhang4.   

Abstract

OBJECTIVE: We sought to compare the prognosis of clival chordomas with different dural penetration and establish the relationship between dural penetration and platelet-derived growth factor receptor (PDGFR)-β signaling pathway.
METHODS: Tumors in Type I (33 cases) showed limited dural penetration, while those in Type II (34 cases) had more serious dural penetration. Cox multivariate regression analysis was used to analyze risk factors affecting survival. Kaplan-Meier analysis measured overall survival (OS) and progression-free survival (PFS). To determine the relationship between dural penetration and PDGFR-β signaling, expression of PDGFR-β, Akt, mammalian target of rapamycin (mTOR), and phosphatase and tensin homolog (PTEN) expression was compared using immunohistochemistry, quantitative reverse transcription polymerase chain reaction, and Western blotting.
RESULTS: Total resection was achieved in 9 cases in Type I and 11 in Type II. There were significant correlations between OS and dural penetration (P = 0.032) and age (P = 0.034). PFS correlated significantly with dural penetration (P = 0.022), gender (P = 0.001), and degree of resection (P = 0.001). Mean OS in Type I was significantly longer than in Type II (P = 0.046). Patients aged <55 years had longer OS than those aged ≥55 years (P = 0.004). Total resection was correlated with longer PFS (P = 0.011). Among patients with tumors totally resected, mean PFS in Type I was significantly longer than in Type II (P = 0.007). Expression of PDGFR-β in Type II was higher than in Type I.
CONCLUSIONS: Clival chordomas have different degrees of dural penetration. Patients with chordomas with serious dural penetration have poorer prognosis. Higher expression of PDGFR-β is related to more serious dural penetration of clival chordomas.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clival chordomas; Dura mater; Penetration; Platelet-derived growth factor receptor-β; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27506406     DOI: 10.1016/j.wneu.2016.07.096

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  9 in total

1.  MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas.

Authors:  J Bai; J Shi; S Zhang; C Zhang; Y Zhai; S Wang; M Li; C Li; P Zhao; S Geng; S Gui; L Jing; Y Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-07       Impact factor: 3.825

2.  SNF5 as a prognostic factor in skull base chordoma.

Authors:  Mingxuan Li; Yixuan Zhai; Jiwei Bai; Shuai Wang; Hua Gao; Chuzhong Li; Songbai Gui; Jiang Du; Yazhuo Zhang
Journal:  J Neurooncol       Date:  2017-12-08       Impact factor: 4.130

3.  Prognostic Value of Cumulative Score Based on Preoperative Fibrinogen and Albumin Level in Skull Base Chordoma.

Authors:  Mingxuan Li; Jiwei Bai; Shuai Wang; Yixuan Zhai; Shuheng Zhang; Chuzhong Li; Jiang Du; Yazhuo Zhang
Journal:  Onco Targets Ther       Date:  2020-08-20       Impact factor: 4.147

4.  Peri-operative prognostic factors for primary skull base chordomas: results from a single-center cohort.

Authors:  Emanuele La Corte; Morgan Broggi; Alberto Raggi; Silvia Schiavolin; Francesco Acerbi; Giovanni Danesi; Mariangela Farinotti; Giovanni Felisati; Alberto Maccari; Bianca Pollo; Marco Saini; Claudia Toppo; Francesca Valvo; Riccardo Ghidoni; Maria Grazia Bruzzone; Francesco DiMeco; Paolo Ferroli
Journal:  Acta Neurochir (Wien)       Date:  2020-01-16       Impact factor: 2.216

5.  Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.

Authors:  Oluwaseun O Akinduro; Paola Suarez-Meade; Diogo Garcia; Desmond A Brown; Rachel Sarabia-Estrada; Steven Attia; Ziya L Gokaslan; Alfredo Quiñones-Hinojosa
Journal:  Target Oncol       Date:  2021-04-24       Impact factor: 4.864

6.  Long and Very-Long-Chain Ceramides Correlate with A More Aggressive Behavior in Skull Base Chordoma Patients.

Authors:  Emanuele La Corte; Michele Dei Cas; Alberto Raggi; Monica Patanè; Morgan Broggi; Silvia Schiavolin; Chiara Calatozzolo; Bianca Pollo; Carlotta Pipolo; Maria Grazia Bruzzone; Giuseppe Campisi; Rita Paroni; Riccardo Ghidoni; Paolo Ferroli
Journal:  Int J Mol Sci       Date:  2019-09-11       Impact factor: 5.923

7.  Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence.

Authors:  Jiwei Bai; Mingxuan Li; Jianxin Shi; Liwei Jing; Yixuan Zhai; Shuheng Zhang; Junmei Wang; Peng Zhao; Chuzhong Li; Songbai Gui; Yazhuo Zhang
Journal:  Neurosurg Rev       Date:  2021-10-08       Impact factor: 3.042

8.  Research hotspots and trends of chordoma: A bibliometric analysis.

Authors:  Jianxuan Gao; Runzhi Huang; Huabin Yin; Dianwen Song; Tong Meng
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

9.  LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma.

Authors:  Jiwei Bai; Yixuan Zhai; Shuai Wang; Mingxuan Li; Shuheng Zhang; Chuzhong Li; Songbai Gui; Qi Li; Yazhuo Zhang
Journal:  Aging (Albany NY)       Date:  2020-06-13       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.